JAPAC Drug Development: Navigating Safety & Regulatory Requirements
HIT Consultant
APRIL 15, 2024
In fact, in 2018, 80% of all biopharma pipeline projects in JAPAC were EBPs, accounting for 75% of the total clinical trial volume in the region. They are also in communication with the sponsor, who is the MAH of the active pharmaceutical ingredient. In comparison to Japan, China has fewer distinctions.
Let's personalize your content